Krystal Biotech Reports FDA Acceptance Of IND Application For Lead Oncology Candidate KB707
Portfolio Pulse from Benzinga Newsdesk
Krystal Biotech has announced that the FDA has accepted its Investigational New Drug (IND) application for its lead oncology candidate KB707.
July 26, 2023 | 8:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Krystal Biotech's stock may see positive movement as the FDA has accepted its IND application for KB707.
The acceptance of an IND application by the FDA is a significant step in the development of a new drug. This news indicates progress in Krystal Biotech's pipeline, which could positively impact investor sentiment and potentially lead to a rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100